{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:37:25Z","timestamp":1770439045184,"version":"3.49.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T00:00:00Z","timestamp":1445904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T00:00:00Z","timestamp":1445904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1038\/tpj.2015.76","type":"journal-article","created":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T11:05:06Z","timestamp":1445943906000},"page":"566-572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort"],"prefix":"10.1038","volume":"16","author":[{"given":"T M","family":"Dodgen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C De J","family":"Labuschagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"van Schalkwyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F E","family":"Steffens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Gaedigk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A D","family":"Cromarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Alessandrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M S","family":"Pepper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,27]]},"reference":[{"key":"BFtpj201576_CR1","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1365-2125.2007.03034.x","volume":"65","author":"U Mehta","year":"2008","unstructured":"Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI . Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV\/AIDS prevalence: prospective observational study. Br J Clin Pharmacol 2008; 65: 396\u2013406.","journal-title":"Br J Clin Pharmacol"},{"key":"BFtpj201576_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.tips.2004.02.007","volume":"25","author":"M Ingelman-Sundberg","year":"2004","unstructured":"Ingelman-Sundberg M . Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004; 25: 193\u2013200.","journal-title":"Trends Pharmacol Sci"},{"key":"BFtpj201576_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","volume":"116","author":"M Ingelman-Sundberg","year":"2007","unstructured":"Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C . Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496\u2013526.","journal-title":"Pharmacol Ther"},{"key":"BFtpj201576_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/03602530902843483","volume":"41","author":"SF Zhou","year":"2009","unstructured":"Zhou SF, Liu JP, Chowbay B . Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41: 89\u2013295.","journal-title":"Drug Metab Rev"},{"key":"BFtpj201576_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/toxsci\/kfq374","volume":"120","author":"I Johansson","year":"2011","unstructured":"Johansson I, Ingelman-Sundberg M . Genetic polymorphism and toxicology\u2014with emphasis on cytochrome p450. Toxicol Sci 2011; 120: 1\u201313.","journal-title":"Toxicol Sci"},{"key":"BFtpj201576_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1124\/pr.58.3.6","volume":"58","author":"SJ Gardiner","year":"2006","unstructured":"Gardiner SJ, Begg EJ . Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006; 58: 521\u2013590.","journal-title":"Pharmacol Rev"},{"key":"BFtpj201576_CR7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.pharmthera.2011.11.002","volume":"133","author":"R Myburgh","year":"2012","unstructured":"Myburgh R, Hochfeld WE, Dodgen TM, Ker J, Pepper MS . Cardiovascular pharmacogenetics. Pharmacol Ther 2012; 133: 280\u2013290.","journal-title":"Pharmacol Ther"},{"key":"BFtpj201576_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2133\/dmpk.DMPK-11-RV-090","volume":"27","author":"M Hiratsuka","year":"2012","unstructured":"Hiratsuka M . In vitro assessment of the allelic variants of cytochrome P450. Drug Metab Pharmacokinet 2012; 27: 68\u201384.","journal-title":"Drug Metab Pharmacokinet"},{"key":"BFtpj201576_CR9","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1634\/theoncologist.2010-0259","volume":"16","author":"MJ Deenen","year":"2011","unstructured":"Deenen MJ, Cats A, Beijnen JH, Schellens JH . Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. Oncologist 2011; 16: 820\u2013834.","journal-title":"Oncologist"},{"key":"BFtpj201576_CR10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2174\/138920011795495286","volume":"12","author":"T Niwa","year":"2011","unstructured":"Niwa T, Murayama N, Yamazaki H . Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition. Curr Drug Metab 2011; 12: 412\u2013435.","journal-title":"Curr Drug Metab"},{"key":"BFtpj201576_CR11","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMra032424","volume":"352","author":"GR Wilkinson","year":"2005","unstructured":"Wilkinson GR . Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211\u20132221.","journal-title":"N Engl J Med"},{"key":"BFtpj201576_CR12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2217\/pgs.12.27","volume":"13","author":"CM Walko","year":"2012","unstructured":"Walko CM, McLeod H . Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment. Pharmacogenomics 2012; 13: 691\u2013697.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201576_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2165\/11318070-000000000-00000","volume":"48","author":"SF Zhou","year":"2009","unstructured":"Zhou SF . Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 2009; 48: 761\u2013804.","journal-title":"Clin Pharmacokinet"},{"key":"BFtpj201576_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2174\/1389200215666140202215316","volume":"15","author":"JK Hicks","year":"2014","unstructured":"Hicks JK, Swen JJ, Gaedigk A . Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Curr Drug Metab 2014; 15: 218\u2013232.","journal-title":"Curr Drug Metab"},{"key":"BFtpj201576_CR15","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3109\/09540261.2013.825581","volume":"25","author":"A Gaedigk","year":"2013","unstructured":"Gaedigk A . Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry 2013; 25: 534\u2013553.","journal-title":"Int Rev Psychiatry"},{"key":"BFtpj201576_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","volume":"5","author":"M Ingelman-Sundberg","year":"2005","unstructured":"Ingelman-Sundberg M . Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5: 6\u201313.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201576_CR17","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1097\/GIM.0b013e318238b38c","volume":"13","author":"SA Scott","year":"2011","unstructured":"Scott SA . Personalizing medicine with clinical pharmacogenetics. Genet Med 2011; 13: 987\u2013995.","journal-title":"Genet Med"},{"key":"BFtpj201576_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2133\/dmpk.DMPK-11-RV-121","volume":"27","author":"LK Teh","year":"2012","unstructured":"Teh LK, Bertilsson L . Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet 2012; 27: 55\u201367.","journal-title":"Drug Metab Pharmacokinet"},{"key":"BFtpj201576_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2217\/pgs.11.134","volume":"13","author":"EJ Begg","year":"2012","unstructured":"Begg EJ, Helsby NA, Jensen BP . Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis. Pharmacogenomics 2012; 13: 83\u201389.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201576_CR20","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1177\/0310057X0002800602","volume":"28","author":"RA Wilcox","year":"2000","unstructured":"Wilcox RA, Owen H . Variable cytochrome P450 2D6 expression and metabolism of codeine and other opioid prodrugs: implications for the Australian anaesthetist. Anaesth Intensive Care 2000; 28: 611\u2013619.","journal-title":"Anaesth Intensive Care"},{"key":"BFtpj201576_CR21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.fpc.0000239974.69464.f2","volume":"17","author":"J Sistonen","year":"2007","unstructured":"Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S . CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007; 17: 93\u2013101.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201576_CR22","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/nature06742","volume":"451","author":"M Jakobsson","year":"2008","unstructured":"Jakobsson M, Scholz SW, Scheet P, Gibbs JR, VanLiere JM, Fung HC et al. Genotype, haplotype and copy-number variation in worldwide human populations. Nature 2008; 451: 998\u20131003.","journal-title":"Nature"},{"key":"BFtpj201576_CR23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/clpt.2012.96","volume":"92","author":"M Whirl-Carrillo","year":"2012","unstructured":"Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012; 92: 414\u2013417.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201576_CR24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/FPC.0b013e32831ebb30","volume":"19","author":"J Sistonen","year":"2009","unstructured":"Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A . Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 2009; 19: 170\u2013179.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201576_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3109\/03602532.2013.783062","volume":"45","author":"M Alessandrini","year":"2013","unstructured":"Alessandrini M, Asfaha S, Dodgen TM, Warnich L, Pepper MS . Cytochrome P450 pharmacogenetics in African populations. Drug Metab Rev 2013; 45: 253\u2013275.","journal-title":"Drug Metab Rev"},{"key":"BFtpj201576_CR26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0026-895X(25)09721-4","volume":"46","author":"I Johansson","year":"1994","unstructured":"Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M . Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46: 452\u2013459.","journal-title":"Mol Pharmacol"},{"key":"BFtpj201576_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00228-007-0445-7","volume":"64","author":"A Gaedigk","year":"2008","unstructured":"Gaedigk A, Coetsee C . The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. Eur J Clin Pharmacol 2008; 64: 465\u2013475.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201576_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00439-010-0836-1","volume":"128","author":"E de Wit","year":"2010","unstructured":"de Wit E, Delport W, Rugamika CE, Meintjes A, Moller M, van Helden PD et al. Genome-wide analysis of the structure of the South African Coloured Population in the Western Cape. Hum Genet 2010; 128: 145\u2013153.","journal-title":"Hum Genet"},{"key":"BFtpj201576_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/hmg\/ddp505","volume":"19","author":"N Patterson","year":"2010","unstructured":"Patterson N, Petersen DC, van der Ross RE, Sudoyo H, Glashoff RH, Marzuki S et al. Genetic structure of a unique admixed population: implications for medical research. Hum Mol Genet 2010; 19: 411\u2013419.","journal-title":"Hum Mol Genet"},{"key":"BFtpj201576_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2174\/187569211796957575","volume":"9","author":"L Warnich","year":"2011","unstructured":"Warnich L, Drogemoller BI, Pepper MS, Dandara C, Wright GE . Pharmacogenomic research in South Africa: lessons learned and future opportunities in the rainbow nation. Curr Pharmacogenomics Person Med 2011; 9: 191\u2013207.","journal-title":"Curr Pharmacogenomics Person Med"},{"key":"BFtpj201576_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-2350-14-20","volume":"14","author":"TM Dodgen","year":"2013","unstructured":"Dodgen TM, Hochfeld WE, Fickl H, Asfaha SM, Durandt C, Rheeder P et al. Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study. BMC Med Genet 2013; 14: 20.","journal-title":"BMC Med Genet"},{"key":"BFtpj201576_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/1479-7364-3-2-169","volume":"3","author":"A Matimba","year":"2009","unstructured":"Matimba A, Del-Favero J, Van Broeckhoven C, Masimirembwa C . Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics 2009; 3: 169\u2013190.","journal-title":"Hum Genomics"},{"key":"BFtpj201576_CR33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1469-1809.2010.00585.x","volume":"74","author":"GE Wright","year":"2010","unstructured":"Wright GE, Niehaus DJ, Drogemoller BI, Koen L, Gaedigk A, Warnich L . Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet 2010; 74: 340\u2013350.","journal-title":"Ann Hum Genet"},{"key":"BFtpj201576_CR34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2217\/pgs.12.207","volume":"14","author":"LK Montane Jaime","year":"2013","unstructured":"Montane Jaime LK, Lalla A, Steimer W, Gaedigk A . Characterization of the CYP2D6 gene locus and metabolic activity in Indo- and Afro-Trinidadians: discovery of novel allelic variants. Pharmacogenomics 2013; 14: 261\u2013276.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201576_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/096032718900800107","volume":"8","author":"DK Sommers","year":"1989","unstructured":"Sommers DK, Moncrieff J, Avenant J . Metoprolol alpha-hydroxylation polymorphism in the San Bushmen of southern Africa. Hum Toxicol 1989; 8: 39\u201343.","journal-title":"Hum Toxicol"},{"key":"BFtpj201576_CR36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/096032718900800506","volume":"8","author":"DK Sommers","year":"1989","unstructured":"Sommers DK, Moncrieff J, Avenant J . Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda. Hum Toxicol 1989; 8: 365\u2013368.","journal-title":"Hum Toxicol"},{"key":"BFtpj201576_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/096032718800700308","volume":"7","author":"DK Sommers","year":"1988","unstructured":"Sommers DK, Moncrieff J, Avenant J . Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa. Hum Toxicol 1988; 7: 273\u2013276.","journal-title":"Hum Toxicol"},{"key":"BFtpj201576_CR38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/096032719101000304","volume":"10","author":"DK Sommers","year":"1991","unstructured":"Sommers DK, Moncrieff J, Avenant JC . Absence of polymorphism of sparteine oxidation in the South African Venda. Hum Exp Toxicol 1991; 10: 175\u2013178.","journal-title":"Hum Exp Toxicol"},{"key":"BFtpj201576_CR39","first-page":"28","volume":"86","author":"DK Sommers","year":"1990","unstructured":"Sommers DK, Moncrieff J, Avenant J . Polymorphism in sparteine oxidation in the Barakwena (Kwengo) of Southern Africa. S Afr J Sci 1990; 86: 28\u201329.","journal-title":"S Afr J Sci"},{"key":"BFtpj201576_CR40","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","volume":"83","author":"A Gaedigk","year":"2008","unstructured":"Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS . The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83: 234\u2013242.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201576_CR41","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/jssc.201000920","volume":"34","author":"TM Dodgen","year":"2011","unstructured":"Dodgen TM, Cromarty AD, Pepper MS . Quantitative plasma analysis using automated online solid-phase extraction with column switching LC-MS\/MS for characterising cytochrome P450 2D6 and 2C19 metabolism. J Sep Sci 2011; 34: 1102\u20131110.","journal-title":"J Sep Sci"},{"key":"BFtpj201576_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1017\/S1092852900020022","volume":"14","author":"J de Leon","year":"2009","unstructured":"de Leon J, Susce MT, Johnson M, Hardin M, Maw L, Shao A et al. DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr 2009; 14: 19\u201334.","journal-title":"CNS Spectr"},{"key":"BFtpj201576_CR43","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1124\/dmd.107.015354","volume":"35","author":"H Shen","year":"2007","unstructured":"Shen H, He MM, Liu H, Wrighton SA, Wang L, Guo B et al. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos 2007; 35: 1292\u20131300.","journal-title":"Drug Metab Dispos"},{"key":"BFtpj201576_CR44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1067\/mcp.2002.120239","volume":"71","author":"A Wennerholm","year":"2002","unstructured":"Wennerholm A, Dandara C, Sayi J, Svensson JO, Abdi YA, Ingelman-Sundberg M et al. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther 2002; 71: 77\u201388.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201576_CR45","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/hmg\/ddt417","volume":"23","author":"D Wang","year":"2014","unstructured":"Wang D, Poi MJ, Sun X, Gaedigk A, Leeder JS, Sadee W . Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet 2014; 23: 268\u2013278.","journal-title":"Hum Mol Genet"},{"key":"BFtpj201576_CR46","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1093\/hmg\/ddu566","volume":"24","author":"D Wang","year":"2015","unstructured":"Wang D, Papp AC, Sun X . Functional characterization of CYP2D6 enhancer polymorphisms. Hum Mol Genet 2015; 24: 1556\u20131562.","journal-title":"Hum Mol Genet"},{"key":"BFtpj201576_CR47","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00228-005-0051-5","volume":"61","author":"C Funck-Brentano","year":"2005","unstructured":"Funck-Brentano C, Boelle PY, Verstuyft C, Bornert C, Becquemont L, Poirier JM . Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol 2005; 61: 821\u2013829.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201576_CR48","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s002280100273","volume":"57","author":"WJ Tamminga","year":"2001","unstructured":"Tamminga WJ, Wemer J, Oosterhuis B, Brakenhoff JP, Gerrits MG, de Zeeuw RA et al. An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19. Eur J Clin Pharmacol 2001; 57: 143\u2013146.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201576_CR49","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00228-006-0250-8","volume":"63","author":"D Frank","year":"2007","unstructured":"Frank D, Jaehde U, Fuhr U . Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 2007; 63: 321\u2013333.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201576_CR50","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/clpt.2009.2","volume":"85","author":"A Gomez","year":"2009","unstructured":"Gomez A, Ingelman-Sundberg M . Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther 2009; 85: 426\u2013430.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201576_CR51","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1742-7843.2007.00121.x","volume":"101","author":"BH Hellum","year":"2007","unstructured":"Hellum BH, Nilsen OG . The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol. Basic Clin Pharmacol Toxicol 2007; 101: 350\u2013358.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"BFtpj201576_CR52","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/mnfr.200600300","volume":"52","author":"BJ Gurley","year":"2008","unstructured":"Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 2008; 52: 755\u2013763.","journal-title":"Mol Nutr Food Res"},{"key":"BFtpj201576_CR53","first-page":"189","volume-title":"South African Health Review, 2007","author":"M Mander","year":"2007","unstructured":"Mander M, Ntuli L, Diederichs N, Mavundla K . Economics of the traditional medicine trade in South Africa. In: Harrison S, Bhana R, Ntuli A (eds) South African Health Review, 2007. Health Systems Trust: Durban: Durban, 2007; pp 189\u2013196."},{"key":"BFtpj201576_CR54","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s002280000116","volume":"56","author":"WM O'Neil","year":"2000","unstructured":"O'Neil WM, Gilfix BM, Markoglou N, Di Girolamo A, Tsoukas CM, Wainer IW . Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome. Eur J Clin Pharmacol 2000; 56: 231\u2013240.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201576_CR55","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00228-009-0777-6","volume":"66","author":"AE Jones","year":"2010","unstructured":"Jones AE, Brown KC, Werner RE, Gotzkowsky K, Gaedigk A, Blake M et al. Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol 2010; 66: 475\u2013485.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201576_CR56","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1365-2710.2012.01333.x","volume":"37","author":"J Jurica","year":"2012","unstructured":"Jurica J, Bartecek R, Zourkova A, Pindurova E, Sulcova A, Kasparek T et al. Serum dextromethorphan\/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice. J Clin Pharm Ther 2012; 37: 486\u2013490.","journal-title":"J Clin Pharm Ther"},{"key":"BFtpj201576_CR57","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1046\/j.1365-2125.1999.00029.x","volume":"48","author":"R Abdul Manap","year":"1999","unstructured":"Abdul Manap R, Wright CE, Gregory A, Rostami-Hodjegan A, Meller ST, Kelm GR et al. The antitussive effect of dextromethorphan in relation to CYP2D6 activity. Br J Clin Pharmacol 1999; 48: 382\u2013387.","journal-title":"Br J Clin Pharmacol"},{"key":"BFtpj201576_CR58","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0022-3565(24)37996-0","volume":"288","author":"JA Desmeules","year":"1999","unstructured":"Desmeules JA, Oestreicher MK, Piguet V, Allaz AF, Dayer P . Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan. J Pharmacol Exp Ther 1999; 288: 607\u2013612.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFtpj201576_CR59","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1067\/mcp.2002.125783","volume":"72","author":"A Gaedigk","year":"2002","unstructured":"Gaedigk A, Bradford LD, Marcucci KA, Leeder JS . Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 2002; 72: 76\u201389.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201576_CR60","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1097\/MPH.0b013e31828e52d2","volume":"35","author":"MM Yee","year":"2013","unstructured":"Yee MM, Josephson C, Hill CE, Harrington R, Castillejo MI, Ramjit R et al. Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease. J Pediatr Hematol Oncol 2013; 35: e301\u2013e305.","journal-title":"J Pediatr Hematol Oncol"},{"key":"BFtpj201576_CR61","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/ajh.23137","volume":"87","author":"P Joly","year":"2012","unstructured":"Joly P, Gagnieu MC, Bardel C, Francina A, Pondarre C, Martin C . Genotypic screening of the main opiate-related polymorphisms in a cohort of 139 sickle cell disease patients. Am J Hematol 2012; 87: 534\u2013536.","journal-title":"Am J Hematol"},{"key":"BFtpj201576_CR62","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/clpt.1991.141","volume":"50","author":"MV Relling","year":"1991","unstructured":"Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE . Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther 1991; 50: 308\u2013313.","journal-title":"Clin Pharmacol Ther"}],"updated-by":[{"DOI":"10.1038\/tpj.2017.20","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T00:00:00Z","timestamp":1500595200000}}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201576.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201576","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201576.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T04:56:37Z","timestamp":1748667397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,27]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["BFtpj201576"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2015.76","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/tpj.2017.20","asserted-by":"object"}]},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,27]]},"assertion":[{"value":"6 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}